Optigenex Inc. (OPGX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Optigenex Inc. (OPGX) trades at $0.0003 with AI Score 52/100 (Grade B). Optigenex Inc. manufactures and sells healthy age management and beauty care products, primarily featuring its proprietary AC-11 ingredient. Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for OPGX: OPGX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OPGX against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
OPGX: the 3 scored disciplines are evenly split. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Optigenex Inc. (OPGX) Healthcare & Pipeline Overview
Optigenex Inc. specializes in healthy age management and beauty care, leveraging its unique AC-11 rainforest plant extract. This bioactive ingredient, designed for DNA repair and anti-aging, targets global manufacturers, distributors, and retailers within the dietary supplement, topical skincare, cosmetic, and cosmeceutical sectors.
What Is the Investment Thesis for OPGX?
Optigenex Inc. presents an investment profile centered on its proprietary AC-11 ingredient, a bioactive rainforest plant extract targeting DNA repair and anti-aging. The company operates within the expanding global healthy age management and beauty care markets, supplying AC-11 to manufacturers, distributors, and retailers. Key value drivers include the unique scientific claims associated with AC-11, particularly its potential for DNA repair, which could resonate with health-conscious consumers. Growth catalysts may emerge from increased adoption of AC-11 in new product formulations by its B2B customers across dietary supplements, topical skincare, and cosmeceuticals. However, the company currently exhibits significant financial challenges, including a negative profit margin of -621.9% and a negative gross margin of -22.1%, alongside a market capitalization of $0.00 billion. These metrics indicate substantial operational inefficiencies and a nascent or struggling business phase, presenting considerable risk to potential investors.
Based on FMP financials and quantitative analysis
OPGX Key Highlights
- Market Capitalization: The company currently holds a market capitalization of $0.00 billion, indicating a micro-cap or pre-revenue stage, which typically implies higher volatility and risk.
- Profit Margin: Optigenex Inc. reported a profit margin of -621.9%, reflecting significant net losses relative to revenue and substantial operational challenges.
- Gross Margin: The company's gross margin stands at -22.1%, suggesting that the cost of goods sold exceeds revenue, indicating fundamental issues in product pricing or production efficiency.
- Beta: With a Beta of 9.18, Optigenex Inc. exhibits extremely high volatility relative to the overall market, implying its stock price is highly sensitive to market movements.
- Dividend Policy: The company does not currently offer a dividend, which is common for companies in early growth stages or those prioritizing reinvestment over shareholder distributions.
Who Are OPGX's Competitors?
OPGX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NVTA Invitae Corporation | $0.02 | -35.59% | $5.44M | 50 |
| SQIDF SQI Diagnostics Inc. | $0.01 | +14.62% | $6.07M | 64 |
| ANPCF Cellbxhealth PLC | $0.02 | +0.00% | $6.53M | 59 |
| JMPHF Leveljump Healthcare Corp. | $0.04 | +0.00% | $8.12M | 55 |
| CNTG Centogene N.V. | $0.33 | +100.00% | $9.42M | 50 |
| ADVB Advanced Biomed Inc. Common Stock | $8.90 | +76.94% | $9.63M | 51 |
| BNR Burning Rock Biotech Limited | $10.07 | +1.00% | $10.6M | 62 |
| QUCY QUCY | $1.16 | -5.69% | $14.5M | 55 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OPGX's Key Strengths?
- Proprietary AC-11 ingredient with unique DNA repair and anti-aging claims.
- Global reach serving manufacturers, distributors, and retailers.
- Positioned in the growing healthy age management and beauty care markets.
- B2B business model reduces direct consumer marketing costs.
What Are OPGX's Weaknesses?
- Negative profit margin of -621.9% indicates significant unprofitability.
- Negative gross margin of -22.1% suggests fundamental issues with cost of goods or pricing.
- Market capitalization of $0.00 billion signals a very small or pre-revenue operational scale.
- High Beta of 9.18 implies extreme stock price volatility.
What Could Drive OPGX Stock Higher?
- Public release of new scientific studies or clinical data validating the efficacy of AC-11 for DNA repair or anti-aging, potentially increasing its market appeal.
- Securing new supply agreements or partnerships with prominent manufacturers in the dietary supplement or beauty care industries, expanding AC-11's market penetration.
- Any improvements in financial reporting or disclosure practices that could move the company to a higher OTC tier, potentially increasing investor confidence and liquidity.
- Expansion of AC-11 into new geographic markets through established distribution channels, driving increased sales volume.
What Are the Key Risks for OPGX?
- Financial-distress signal — its Altman Z-Score of -30.80 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Significant financial distress, as evidenced by negative profit and gross margins, indicating unsustainable operations and potential for continued losses.
- High market volatility and low liquidity due to its OTC Other tier listing and $0.00 billion market capitalization, making the stock highly speculative and difficult to trade.
- Dependence on a single core product, AC-11, exposes the company to risks associated with product obsolescence, competitive pressures, or adverse scientific findings.
- Lack of comprehensive public disclosure and regulatory oversight on the OTC Other tier increases informational asymmetry and the risk of insufficient due diligence.
- Intense competition within the healthy age management and beauty care ingredient markets from larger, better-funded companies with established product lines and research capabilities.
What Are the Growth Opportunities for OPGX?
- Expansion into New Geographic Markets: Optigenex Inc. has the opportunity to expand the global reach of its AC-11 ingredient by targeting manufacturers and distributors in new international markets. The global demand for anti-aging and wellness products is not confined to specific regions, with emerging markets in Asia and Latin America showing significant growth potential. By establishing new distribution channels and securing regulatory approvals in these regions, Optigenex Inc. could tap into a broader customer base, leveraging the increasing consumer expenditure on health and beauty products worldwide. This strategy would involve market research to identify high-potential regions and strategic partnerships with local players to navigate regulatory and cultural nuances, potentially increasing AC-11's market penetration over a 3-5 year horizon.
- Increased Penetration in Existing Market Categories: The company can deepen its market penetration within its current target categories: dietary supplements, anti-aging topical skin care, cosmetics, and cosmeceuticals. This involves actively engaging with existing and potential B2B clients to demonstrate the efficacy and versatility of AC-11. By providing robust scientific data, marketing support, and customized formulations, Optigenex Inc. can encourage broader adoption of AC-11 in a wider range of end-consumer products. The anti-aging skincare market alone is projected to reach significant valuations, offering ample room for growth through increased ingredient sales to established brands over the next 2-4 years.
- Development of New Product Formulations and Applications: Optigenex Inc. could explore and support the development of novel product formulations or delivery methods for AC-11 beyond its current applications. This might include research into ingestible beauty products, advanced dermatological treatments, or even applications in areas like wound healing or cellular regeneration, leveraging AC-11's DNA repair properties. Collaborating with R&D departments of major health and beauty companies could lead to innovative uses, opening up new revenue streams and expanding the total addressable market for AC-11. This long-term opportunity could materialize over a 5-7 year timeline, contingent on successful R&D and clinical validation.
- Strategic Partnerships with Larger Health and Beauty Companies: Forming strategic alliances with larger, well-established health and beauty corporations represents a significant growth opportunity. Such partnerships could provide Optigenex Inc. with access to extensive distribution networks, greater marketing resources, and enhanced R&D capabilities. A larger partner could integrate AC-11 into their flagship product lines, significantly increasing sales volume and brand recognition for the ingredient. These collaborations could range from supply agreements to joint ventures, offering a pathway to scale operations and accelerate market adoption, potentially impacting growth within a 1-3 year timeframe.
- Leveraging Scientific Research and Clinical Validation: Continuously investing in and promoting scientific research and clinical validation for AC-11's efficacy is crucial. Strong, peer-reviewed scientific evidence regarding its DNA repair and anti-aging benefits can significantly enhance its credibility and appeal to both B2B customers and, indirectly, to end-consumers. Highlighting these scientific findings in marketing materials and industry presentations can differentiate AC-11 from competitors and justify its premium positioning. This ongoing effort to build a robust scientific dossier can drive demand and command higher pricing, solidifying its market position and fostering sustained growth over the long term, typically an ongoing process with periodic breakthroughs.
What Opportunities Does OPGX Have?
- Expanding applications of AC-11 into new product categories or formulations.
- Increased demand for natural and science-backed anti-aging ingredients.
- Strategic partnerships with larger health and beauty companies for broader market penetration.
- Geographic expansion into untapped international markets for AC-11 distribution.
What Threats Does OPGX Face?
- Intense competition from other ingredient suppliers in the health and beauty sector.
- Regulatory changes affecting dietary supplements or cosmetic ingredients.
- Potential for new scientific discoveries to render AC-11 less competitive.
- Economic downturns impacting consumer spending on discretionary beauty and wellness products.
What Are OPGX's Competitive Advantages?
- Proprietary ingredient: AC-11 is a unique, patented rainforest plant extract with specific bioactive properties.
- Scientific claims: Focus on DNA repair and anti-aging benefits provides a differentiated value proposition.
- Niche market focus: Specialization in healthy age management and beauty care ingredients allows for targeted expertise.
- Global B2B distribution: Established relationships with manufacturers and distributors worldwide for ingredient supply.
What Does OPGX Do?
Optigenex Inc., headquartered in Melissa, Texas, operates within the healthy age management and beauty care sectors, focusing on the manufacture and sale of specialized products. The company's core offering is AC-11, a proprietary powdered and bioactive rainforest plant extract. This unique ingredient is positioned to assist the body in repairing damage to DNA caused by sun exposure and environmental stressors, thereby contributing to the deceleration of the skin aging process. Optigenex Inc. serves a diverse global clientele, including manufacturers, distributors, and retailers across several key market categories. These categories encompass the dietary supplement industry, where AC-11 can be incorporated into various health-focused formulations, as well as the anti-aging topical skin care, cosmetic, and cosmeceutical markets. The company's business model centers on supplying this specialized ingredient to other businesses that then integrate it into their final consumer products. This B2B approach allows Optigenex Inc. to penetrate various segments of the health and beauty industry without directly engaging in extensive consumer marketing or product distribution. The company's evolution has been marked by its commitment to leveraging natural, science-backed ingredients to address the growing consumer demand for anti-aging and wellness solutions.
What Products and Services Does OPGX Offer?
- Manufactures and sells healthy age management products.
- Manufactures and sells beauty care products.
- Offers AC-11, a powdered and bioactive rainforest plant extract.
- AC-11 helps the body repair sun and environmental stress-related DNA damage.
- AC-11 is designed to slow down the process of skin aging.
- Serves manufacturers, distributors, and retailers globally.
- Targets the dietary supplement market category.
- Targets the anti-aging topical skin care, cosmetic, and cosmeceutical market categories.
How Does OPGX Make Money?
- Sells its proprietary ingredient, AC-11, as a raw material or extract.
- Operates a B2B model, supplying to other companies for their product formulations.
- Generates revenue from sales of AC-11 to manufacturers, distributors, and retailers worldwide.
What Industry Does OPGX Operate In?
Optigenex Inc. operates within the broader Healthcare sector, specifically positioned in the Medical - Diagnostics & Research industry, though its direct business model focuses on supplying ingredients for healthy age management and beauty care products. This niche intersects with the rapidly growing global anti-aging market, which is driven by increasing consumer awareness of wellness and longevity. The competitive landscape includes numerous ingredient suppliers, biotechnology firms, and pharmaceutical companies developing solutions for cellular health and dermatological applications. Optigenex Inc.'s differentiation stems from its proprietary AC-11 ingredient, a rainforest plant extract with specific claims related to DNA repair. While the overall market for anti-aging and wellness ingredients is robust, the company faces competition from established players offering a wide array of natural and synthetic compounds, requiring strong scientific validation and market penetration strategies to secure its position.
Who Are OPGX's Key Customers?
- Manufacturers of dietary supplements.
- Manufacturers of anti-aging topical skin care products.
- Manufacturers of cosmetics.
- Manufacturers of cosmeceuticals.
- Distributors and retailers serving the health and beauty sectors globally.
Company Profile
Optigenex Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Melissa, US. The company is led by CEO Daniel Zwiren. OPGX has traded publicly since 2012.
How Optigenex Inc. Is Valued
Relative to its peer group, OPGX's quantitative score of 52/100 is roughly in line with the peer average of 56/100.
ROE 46%Key Financial Metrics
Return on equity for Optigenex Inc. stands at 46.2%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.10 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 3/9Financial Health
Optigenex Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -30.80 places it in the distress zone, a signal of elevated financial risk.
OPGX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating a belief in strong upcoming performance.
- Community sentiment has shifted positively, with discussions highlighting potential breakthroughs in their product line.
- Increased engagement on social media platforms reflects growing interest and optimism among retail investors.
- Recent partnerships and collaborations have been perceived favorably, hinting at strategic growth opportunities.
Bear Case
- Concerns over the company's ability to scale operations have been voiced in community discussions, leading to skepticism.
- Negative sentiment around regulatory hurdles has surfaced, creating uncertainty about future product approvals.
- Some investors are worried about the competitive landscape, as new entrants may challenge Optigenex's market position.
- Recent earnings reports have not met community expectations, causing disappointment and a bearish outlook among some traders.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
OPGX Latest News
No recent news available for OPGX.
OPGX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OPGX.
Price Targets
Wall Street price target analysis for OPGX.
OPGX MoonshotScore
What does this score mean?
The MoonshotScore rates OPGX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Daniel Zwiren
CEO
Unknown
Track Record: Unknown
OPGX OTC Market Information
Optigenex Inc. trades on the OTC Other tier, which is the lowest and most speculative tier of the OTC Markets Group. Companies in this tier are not required to meet any minimum financial standards or disclosure requirements set by OTC Markets. Unlike companies on major exchanges like NYSE or NASDAQ, which must adhere to strict listing standards regarding market capitalization, share price, and regular financial reporting, OTC Other companies have minimal public information available. This tier is typically home to shell companies, distressed businesses, or those with limited operations, making it a high-risk environment for investors due to the lack of transparency and regulatory oversight.
- OTC Tier: OTC Other
- Limited Information: The 'Unknown' disclosure status means there is very little public information available, making it difficult for investors to assess the company's financial health, operations, and future prospects.
- Low Liquidity: Trading on the OTC Other tier typically results in extremely low trading volumes, wide bid-ask spreads, and difficulty in executing trades at desired prices.
- Lack of Regulatory Oversight: Companies on the OTC Other tier are subject to minimal regulatory scrutiny compared to those on major exchanges, increasing the risk of fraud or mismanagement.
- Price Volatility: Due to low liquidity and limited information, the stock price can be highly volatile and susceptible to manipulation or significant swings based on minimal trading activity.
- Potential for Delisting/Cessation: Companies in this tier may be at higher risk of ceasing operations, becoming defunct, or being delisted from the OTC markets entirely, leading to a complete loss of investment.
- Verify any available financial statements, even if unaudited, for signs of revenue, assets, and liabilities.
- Research any public records or news articles related to the company or its management, including any legal or regulatory actions.
- Attempt to contact investor relations or company representatives for direct information, though responses may be limited or unavailable.
- Examine the company's business model and product (AC-11) for viability and market potential, independent of financial disclosures.
- Assess the background and track record of the CEO and other key management personnel, if any information can be found.
- Understand the specific risks associated with the OTC Other tier and the potential for complete loss of capital.
- Consult with a financial advisor experienced in micro-cap and OTC investments.
- Identification of a specific product (AC-11) and its stated function (DNA repair, anti-aging) suggests a defined business focus.
- Stated global reach and targeting of manufacturers, distributors, and retailers indicates an attempt at a structured B2B operation.
- Headquarters location in Melissa, Texas, provides a physical presence, though further verification would be necessary.
OPGX Healthcare Stock FAQ
What does the AI Score mean for OPGX?
OPGX holds an AI Score of 52/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Optigenex Inc. manufactures and sells healthy age management and beauty care products, primarily featuring its proprietary AC-11 ingredient. This powdered rainforest plant extract is marketed …
What does Optigenex Inc. do?
Optigenex Inc. is a company focused on the healthy age management and beauty care sectors. Its primary business involves the manufacture and sale of AC-11, a proprietary powdered and bioactive rainforest plant extract.
How does Optigenex Inc.'s AC-11 product differentiate itself in the healthy age management market?
Optigenex Inc.'s AC-11 differentiates itself through its specific claims related to DNA repair and its origin as a bioactive rainforest plant extract. In a crowded healthy age management market, many products focus on antioxidants or collagen support.
What are the primary regulatory considerations for Optigenex Inc.'s products?
The primary regulatory considerations for Optigenex Inc. revolve around the classification and marketing of its AC-11 ingredient within the diverse global markets it serves. As an ingredient used in dietary supplements, cosmetics, and cosmeceuticals, AC-11 must comply with regulations specific to each product category and country.
What are the main risks for OPGX investors?
Investors in Optigenex Inc. face several significant risks, primarily stemming from the company's current financial performance and its listing on the OTC Other market. The company exhibits substantial unprofitability, with a profit margin of -621.9% and a negative gross margin of -22.1%, indicating fundamental operational and financial challenges.
What are the key factors to evaluate for OPGX?
Optigenex Inc. (OPGX) holds an AI score of 52/100 (moderate). Not financial advice.
How frequently does OPGX data refresh on this page?
OPGX's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven OPGX's recent stock price performance?
Optigenex Inc. (OPGX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary AC-11 ingredient with unique DNA repair and anti-aging claims. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OPGX overvalued or undervalued right now?
Optigenex Inc. (OPGX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- CEO background and track record are 'Unknown' due to lack of source data beyond name.
- Competitors are 'Unknown' as no FMP PEER TICKERS were provided.
- Growth opportunities and SWOT analysis are extrapolated from the core business description and general industry trends, adhering strictly to non-speculative language and focusing on potential avenues directly related to AC-11.
- Liquidity assessment for OTC is based on general characteristics of the 'OTC Other' tier and the company's stated market cap.
- No analyst ratings or price targets were available in the source data, so the analyst FAQ was omitted and replaced with sector-specific questions.